Bispecific Antibodies in Multiple Myeloma: Present and Future.

ABSTRACT: Despite many recent advances in therapy, there is still no plateau in overall survival curves in multiple myeloma. Bispecific antibodies are a novel immunotherapeutic approach designed to bind antigens on malignant plasma cells and cytotoxic immune effector cells. Early-phase clinical trials targeting B-cell maturation antigen (BCMA), GPRC5D, and FcRH5 have demonstrated a favorable safety profile, with mainly low-grade cytokine release syndrome, cytopenias, and infections. Although dose escalation is ongoing in several studies, early efficacy data show response rates in the most active dose cohorts between 61% and 83% with many deep responses; however, durability remains to be established. Further clinical trial data are eagerly anticipated.

Significance

Overall survival of triple-c

SUBMITTER: Lancman G 

PROVIDER: S-EPMC8510808 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature